金属配合物的靶向化疗
Targeted Chemotherapy with Metal Complexes.
作者信息
Weidmann Alyson G, Komor Alexis C, Barton Jacqueline K
机构信息
Division of Chemistry and Chemical Engineering, California Institute of Technology, Pasadena, CA 91125.
出版信息
Comments Mod Chem A Comments Inorg Chem. 2014 May;34(3-4):114-123. doi: 10.1080/02603594.2014.890099.
Abstract
Classical chemotherapeutics, such as cisplatin and its analogues, have been highly successful in the clinic, yet improvements can certainly be made, given the significant side effects associated with the killing of healthy cells. Recent advances in the field of chemotherapy include the development of targeted anticancer agents, compounds that are directed towards a specific biomarker of cancer, with the hopes that such targeted therapies might have reduced side effects given their greater selectivity. Here we discuss several transition metal complexes that are tailored towards various biomolecules associated with cancer. Most notably, the success of rhodium metalloinsertors, which specifically bind to nucleic acid base mismatches in DNA, highlight the enormous potential of this exciting new strategy.
摘要
经典化疗药物，如顺铂及其类似物，在临床上取得了巨大成功，但鉴于其在杀死健康细胞时会产生严重副作用，仍有改进的空间。化疗领域的最新进展包括开发靶向抗癌药物，即针对癌症特定生物标志物的化合物，希望这类靶向疗法因其更高的选择性而可能减少副作用。在此，我们讨论几种针对与癌症相关的各种生物分子设计的过渡金属配合物。最值得注意的是，铑金属插入剂能够特异性结合DNA中的核酸碱基错配，其成功突出了这一令人兴奋的新策略的巨大潜力。
相似文献
1
Targeted Chemotherapy with Metal Complexes.金属配合物的靶向化疗
Comments Mod Chem A Comments Inorg Chem. 2014 May;34(3-4):114-123. doi: 10.1080/02603594.2014.890099.
2
Targeting DNA Mismatches with Rhodium Metalloinsertors.用铑金属插入剂靶向DNA错配
Inorganica Chim Acta. 2016 Oct 1;452:3-11. doi: 10.1016/j.ica.2016.01.021. Epub 2016 Jan 16.
3
A Family of Rhodium Complexes with Selective Toxicity toward Mismatch Repair-Deficient Cancers.一种具有错配修复缺陷型癌症选择性毒性的铑配合物家族。
J Am Chem Soc. 2018 Apr 25;140(16):5612-5624. doi: 10.1021/jacs.8b02271. Epub 2018 Apr 17.
4
An unusual ligand coordination gives rise to a new family of rhodium metalloinsertors with improved selectivity and potency.一种不同寻常的配体配位产生了一类具有更高选择性和效力的新型铑金属插入剂。
J Am Chem Soc. 2014 Oct 8;136(40):14160-72. doi: 10.1021/ja5072064. Epub 2014 Sep 25.
5
Rhodium Complexes Targeting DNA Mismatches as a Basis for New Therapeutics in Cancers Deficient in Mismatch Repair.靶向 DNA 错配的铑配合物作为错配修复缺陷癌症新疗法的基础。
Biochemistry. 2021 Jul 6;60(26):2055-2063. doi: 10.1021/acs.biochem.1c00302. Epub 2021 Jun 11.
6
Cell-selective biological activity of rhodium metalloinsertors correlates with subcellular localization.金属插入试剂的铑的细胞选择性生物活性与亚细胞定位相关。
J Am Chem Soc. 2012 Nov 21;134(46):19223-33. doi: 10.1021/ja3090687. Epub 2012 Nov 8.
7
Biological effects of simple changes in functionality on rhodium metalloinsertors.简单改变功能对铑金属插入试剂的生物学效应。
Philos Trans A Math Phys Eng Sci. 2013 Jun 17;371(1995):20120117. doi: 10.1098/rsta.2012.0117. Print 2013 Jul 28.
8
DNA mismatch binding and antiproliferative activity of rhodium metalloinsertors.铑金属插入剂的DNA错配结合及抗增殖活性
J Am Chem Soc. 2009 Feb 18;131(6):2359-66. doi: 10.1021/ja8081044.
9
Cell-Selective Cytotoxicity of a Fluorescent Rhodium Metalloinsertor Conjugate Results from Irreversible DNA Damage at Base Pair Mismatches.荧光铑金属插入剂缀合物的细胞选择性细胞毒性源于碱基错配处的不可逆 DNA 损伤。
Biochemistry. 2020 Feb 11;59(5):717-726. doi: 10.1021/acs.biochem.9b01037. Epub 2020 Jan 30.
10
Selective cytotoxicity of rhodium metalloinsertors in mismatch repair-deficient cells.错配修复缺陷细胞中铑金属插入剂的选择性细胞毒性。
Biochemistry. 2011 Dec 20;50(50):10919-28. doi: 10.1021/bi2015822. Epub 2011 Nov 21.
引用本文的文献
1
Crystal Design, Antitumor Activity and Molecular Docking of Novel Palladium(II) and Gold(III) Complexes with a Thiosemicarbazone Ligand.新型钯(II)和金(III)配合物的晶体设计、抗肿瘤活性及分子对接研究：含硫代半卡巴腙配体。
Int J Mol Sci. 2023 Jul 14;24(14):11442. doi: 10.3390/ijms241411442.
2
Highlights of New Strategies to Increase the Efficacy of Transition Metal Complexes for Cancer Treatments.提高过渡金属配合物治疗癌症疗效的新策略要点。
Molecules. 2022 Dec 29;28(1):273. doi: 10.3390/molecules28010273.
3
Systemic Anticancer Therapy Details and Dental Adverse Effects in Children.儿童全身抗癌治疗详情及牙科不良反应。
Int J Environ Res Public Health. 2022 Jun 6;19(11):6936. doi: 10.3390/ijerph19116936.
4
Peptide-Drug Conjugates and Their Targets in Advanced Cancer Therapies.肽-药物偶联物及其在晚期癌症治疗中的靶点
Front Chem. 2020 Jul 7;8:571. doi: 10.3389/fchem.2020.00571. eCollection 2020.
5
In vivo anticancer activity of a rhodium metalloinsertor in the HCT116 xenograft tumor model.在 HCT116 异种移植肿瘤模型中金属插入试剂的体内抗癌活性。
Proc Natl Acad Sci U S A. 2020 Jul 28;117(30):17535-17542. doi: 10.1073/pnas.2006569117. Epub 2020 Jul 13.
6
Synthesis, Characterization and Biological Evaluation of Metal Adamantyl 2-Pyridylhydrazone Complexes.金刚烷基 2-吡啶甲酰腙金属配合物的合成、表征及生物学评价。
Molecules. 2020 May 29;25(11):2530. doi: 10.3390/molecules25112530.
7
Discovery of a Ruthenium Complex for the Theranosis of Glioma through Targeting the Mitochondrial DNA with Bioinformatic Methods.通过生物信息学方法靶向线粒体 DNA 用于神经胶质瘤治疗的钌配合物的发现。
Int J Mol Sci. 2019 Sep 19;20(18):4643. doi: 10.3390/ijms20184643.
8
Unusual Role of Excited State Mixing in the Enhancement of Photoinduced Ligand Exchange in Ru(II) Complexes.激发态混合在增强 Ru(II) 配合物光诱导配体交换中的不寻常作用。
J Am Chem Soc. 2017 Dec 20;139(50):18295-18306. doi: 10.1021/jacs.7b09937. Epub 2017 Dec 11.
9
Clinical Risk Factors Influencing Dental Developmental Disturbances in Childhood Cancer Survivors.影响儿童癌症幸存者牙齿发育障碍的临床危险因素。
Cancer Res Treat. 2018 Jul;50(3):926-935. doi: 10.4143/crt.2017.296. Epub 2017 Oct 10.
10
Rhodium metalloinsertor binding generates a lesion with selective cytotoxicity for mismatch repair-deficient cells.铑金属插入剂结合生成一种具有错配修复缺陷细胞选择性细胞毒性的损伤。
Proc Natl Acad Sci U S A. 2017 Jul 3;114(27):6948-6953. doi: 10.1073/pnas.1706665114. Epub 2017 Jun 20.
本文引用的文献
1
An inducible, isogenic cancer cell line system for targeting the state of mismatch repair deficiency.诱导型、同基因的癌细胞系系统，用于靶向错配修复缺陷状态。
PLoS One. 2013 Oct 29;8(10):e78726. doi: 10.1371/journal.pone.0078726. eCollection 2013.
2
Targeting mitochondrial DNA with a platinum-based anticancer agent.用一种铂类抗癌剂靶向线粒体DNA。
Chem Biol. 2013 Nov 21;20(11):1323-8. doi: 10.1016/j.chembiol.2013.08.010. Epub 2013 Oct 31.
3
Biological effects of simple changes in functionality on rhodium metalloinsertors.简单改变功能对铑金属插入试剂的生物学效应。
Philos Trans A Math Phys Eng Sci. 2013 Jun 17;371(1995):20120117. doi: 10.1098/rsta.2012.0117. Print 2013 Jul 28.
4
The molecular mechanisms of antimetastatic ruthenium compounds explored through DIGE proteomics.通过 DIGE 蛋白质组学探索抗转移钌化合物的分子机制。
J Inorg Biochem. 2013 Jan;118:94-9. doi: 10.1016/j.jinorgbio.2012.10.003. Epub 2012 Oct 14.
5
Cell-selective biological activity of rhodium metalloinsertors correlates with subcellular localization.金属插入试剂的铑的细胞选择性生物活性与亚细胞定位相关。
J Am Chem Soc. 2012 Nov 21;134(46):19223-33. doi: 10.1021/ja3090687. Epub 2012 Nov 8.
6
Global profiling of protein kinase activities in cancer cells by mass spectrometry.利用质谱技术对癌细胞中蛋白激酶活性进行全局分析。
J Proteomics. 2012 Dec 21;77:492-503. doi: 10.1016/j.jprot.2012.09.029. Epub 2012 Oct 4.
7
Crystal structure of Δ-[Ru(bpy)₂dppz]²⁺ bound to mismatched DNA reveals side-by-side metalloinsertion and intercalation.Δ-[Ru(bpy)₂dppz]²⁺与错配 DNA 结合的晶体结构揭示了并排的金属插入和嵌入。
Nat Chem. 2012 Jun 10;4(8):615-20. doi: 10.1038/nchem.1375.
8
Selective cytotoxicity of rhodium metalloinsertors in mismatch repair-deficient cells.错配修复缺陷细胞中铑金属插入剂的选择性细胞毒性。
Biochemistry. 2011 Dec 20;50(50):10919-28. doi: 10.1021/bi2015822. Epub 2011 Nov 21.
9
Structurally sophisticated octahedral metal complexes as highly selective protein kinase inhibitors.结构复杂的八面体金属配合物作为高选择性的蛋白激酶抑制剂。
J Am Chem Soc. 2011 Apr 20;133(15):5976-86. doi: 10.1021/ja1112996. Epub 2011 Mar 29.
10
The status of platinum anticancer drugs in the clinic and in clinical trials.铂类抗癌药物在临床和临床试验中的地位。
Dalton Trans. 2010 Sep 21;39(35):8113-27. doi: 10.1039/c0dt00292e. Epub 2010 Jun 30.
Zotero 插件